Therapy Areas: Diabetes
The Mundipharma network launches type-two diabetes mellitus treatments in Norway
22 March 2019 -

The Mundipharma network of independent associated companies has introduced the type-two diabetes mellitus treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway, it was reported yesterday.

In line with the collaboration with Janssen Pharmaceutica NV, Mundipharma now distributes and markets these treatments across 18 countries in the European Economic Area and Switzerland. With the launch in Norway, Invokana and Vokanamet are now offered across the whole of Scandinavia, following launches in Sweden and Denmark.

Invokana is a once-daily oral tablet and part of the sodium glucose co-transporter 2 (SGLT2) inhibitor class and has been approved in the European Union since 2013. Vokanamet integrates two oral glucose-lowering medicinal products (canagliflozin and metformin) with different and complementary mechanisms of action.

Login
Username:

Password: